Study of the Telomerase HTERT Fraction, PCNA and CD34 Expression on Pituitary Adenomas. Association with Clinical and Demographic Characteristics

Overview

Journal J Neurooncol

Publisher Springer

Date 2007 Mar 16

PMID 17361328

Citations 4

Authors

Alma Ortiz-Plata

Martha Lilia Tena Suck

Mario Lopez-Gomez

Alfonso Heras

Aurora Sanchez Garcia

Affiliations

Soon will be listed here.

Abstract

To determine the frequency of human telomerase reverse transcriptase (hTERT) catalytic fraction expression and its association with clinical and demographic characteristics of the patient, as well as with the expression of CD34 and proliferating cell nuclear antigen (PCNA) indexes on adenohypophyseal hormone tissues. A transverse study was realized with 49 cases of hypophyseal adenoma with analysis type cases and controls. The different adenohypophyseal hormones [prolactin (PRL), growth hormone (GH), follicle stimulating hormone, luteinizing hormone, thyroid gland stimulant hormone, adrenocorticotropic hormone (ACTH)], the catalytic fraction of the telomerase hTERT, the PCNA index and the CD34 density were determined by means of immunohistochemical techniques. The clinical, demographic and histopathological characteristics of the patients with and without hTERT expression were compared by means of Pearson's Chi-squared, Fisher's exact test and Mann-Whitney's U. Twenty-eight point six percent of the adenomas had positive expression for hTERT. The variables significantly correlated with hTERT's expression were younger age of presentation, diagnostic of adenoma producer, higher PCNA index, higher CD34 density, increased GH on serum and the expression on PRL tissue, GH and ACTH. Tobacco history had a negative association with hTERT's expression. The telomerase could be a marker of cellular proliferation associated with angiogenesis and hormonal activity. Evaluation of these variables could provide information about their biological behavior.

Citing Articles

Telomerase expression in clinically non-functioning pituitary adenomas.

Ogino L, Lamback E, Guterres A, de Azeredo Lima C, Henriques D, Barbosa M Endocrine. 2020; 72(1):208-215.

PMID: 33090306 DOI: 10.1007/s12020-020-02524-w.

TERT promoter methylation is significantly associated with TERT upregulation and disease progression in pituitary adenomas.

Miyake Y, Adachi J, Suzuki T, Mishima K, Araki R, Mizuno R J Neurooncol. 2018; 141(1):131-138.

PMID: 30392088 DOI: 10.1007/s11060-018-03016-8.

Telomere length and telomerase expression in pituitary tumors.

Martins C, Santana-Lemos B, Saggioro F, Neder L, Machado H, Moreira A J Endocrinol Invest. 2015; 38(11):1243-6.

PMID: 25952298 DOI: 10.1007/s40618-015-0298-3.

Telomerase and the endocrine system.

Pacini F, Cantara S, Capezzone M, Marchisotta S Nat Rev Endocrinol. 2011; 7(7):420-30.

PMID: 21448143 DOI: 10.1038/nrendo.2011.52.

References

Yamada S, Takada K . Angiogenesis in pituitary adenomas. Microsc Res Tech. 2003; 60(2):236-43. DOI: 10.1002/jemt.10262. View

Harley C, Futcher A, Greider C . Telomeres shorten during ageing of human fibroblasts. Nature. 1990; 345(6274):458-60. DOI: 10.1038/345458a0. View

Lynch H, Brand R, Lynch J, Fusaro R, Kern S . Hereditary factors in pancreatic cancer. J Hepatobiliary Pancreat Surg. 2002; 9(1):12-31. DOI: 10.1007/s005340200001. View

Xia Y, Zhao Y, Marcus J, Jimenez P, Ruben S, Moore P . Effects of keratinocyte growth factor-2 (KGF-2) on wound healing in an ischaemia-impaired rabbit ear model and on scar formation. J Pathol. 1999; 188(4):431-8. DOI: 10.1002/(SICI)1096-9896(199908)188:4<431::AID-PATH362>3.0.CO;2-B. View

Kotoula V, Barbanis S, Nikolakaki E, Koufoyannis D, Papadimitriou C, Karkavelas G . Relative expression of human telomerase catalytic subunit (hTERT) transcripts in astrocytic gliomas. Acta Neuropathol. 2004; 107(5):443-51. DOI: 10.1007/s00401-004-0832-4. View

Nakatani K, Yoshimi N, Mori H, Yoshimura S, Sakai H, Shinoda J . The significant role of telomerase activity in human brain tumors. Cancer. 1997; 80(3):471-6. DOI: 10.1002/(sici)1097-0142(19970801)80:3<471::aid-cncr15>3.0.co;2-u. View

Dong C, Masutomi K, Hahn W . Telomerase: regulation, function and transformation. Crit Rev Oncol Hematol. 2005; 54(2):85-93. DOI: 10.1016/j.critrevonc.2004.12.005. View

Tella Junior O, Herculano M, Delcelo R . [Pituitary adenomas: relationship between invasiveness and proliferative cell nuclear index]. Arq Neuropsiquiatr. 2000; 58(4):1055-63. View

Andersson K . Mecamylamine pretreatment counteracts cigarette smoke induced changes in hypothalamic catecholamine neuron systems and in anterior pituitary function. Acta Physiol Scand. 1985; 125(3):445-52. DOI: 10.1111/j.1748-1716.1985.tb07741.x. View

10.

Asa S . Diseases of the pituitary. Neurosurg Clin N Am. 1994; 5(1):71-95. View

11.

Bravo R, Frank R, Blundell P . Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature. 1987; 326(6112):515-7. DOI: 10.1038/326515a0. View

12.

Fuxe K, Andersson K, Eneroth P, Harfstrand A, Agnati L . Neuroendocrine actions of nicotine and of exposure to cigarette smoke: medical implications. Psychoneuroendocrinology. 1989; 14(1-2):19-41. DOI: 10.1016/0306-4530(89)90054-1. View

13.

Li T, BROWNE R, Matthews J . Quantification of PCNA+ cells within odontogenic jaw cyst epithelium. J Oral Pathol Med. 1994; 23(4):184-9. DOI: 10.1111/j.1600-0714.1994.tb01110.x. View

14.

Hurley S, McNeil J, Donnan G, Forbes A, Salzberg M, Giles G . Tobacco smoking and alcohol consumption as risk factors for glioma: a case-control study in Melbourne, Australia. J Epidemiol Community Health. 1996; 50(4):442-6. PMC: 1060316. DOI: 10.1136/jech.50.4.442. View

15.

Sasco A, Vainio H . From in utero and childhood exposure to parental smoking to childhood cancer: a possible link and the need for action. Hum Exp Toxicol. 1999; 18(4):192-201. DOI: 10.1191/096032799678839905. View

16.

Schreiber S, Saeger W, Ludecke D . Proliferation markers in different types of clinically non-secreting pituitary adenomas. Pituitary. 2000; 1(3-4):213-20. DOI: 10.1023/a:1009933820856. View

17.

Thapar K, Kovacs K, Scheithauer B, Stefaneanu L, Horvath E, Pernicone P . Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery. 1996; 38(1):99-106; discussion 106-7. DOI: 10.1097/00006123-199601000-00024. View

18.

Mesquita M, Martin L, Kayath M . Adrenocorticotropin-Producing Pituitary Carcinoma with Expression of c-erbB-2 and High PCNA Index: A Comparative Study with Pituitary Adenomas and Normal Pituitary Tissues. Endocr Pathol. 2002; 9(1):53-62. DOI: 10.1007/BF02739952. View

19.

Wolfsberger S, Wunderer J, Zachenhofer I, Czech T, Bocher-Schwarz H, Hainfellner J . Expression of cell proliferation markers in pituitary adenomas--correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha. Acta Neurochir (Wien). 2004; 146(8):831-9. DOI: 10.1007/s00701-004-0298-0. View

20.

Kapoor D, Jones T . Smoking and hormones in health and endocrine disorders. Eur J Endocrinol. 2005; 152(4):491-9. DOI: 10.1530/eje.1.01867. View